Taken together, these findings unveil that CB1R overactivation is a driving mechanism of CRBN deficiency-linked ARNSID and anticipate that the antagonism of CB1R could constitute a new therapy for this orphan disease. The gene discussed is CRBN; the disease is autosomal recessive non-syndromic intellectual disability.